As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid scientific advice for policymakers and public health authorities on ways to ...
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...
Please provide your email address to receive an email when new articles are posted on . Adults aged 75 years or older should receive a protein subunit respiratory syncytial virus vaccine. Adults aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results